Emmanuel Papadakis analyst DEUTSCHE BANK

Currently out of the existing stock ratings of Emmanuel Papadakis, 29 are a SELL (27.1%), 40 are a HOLD (37.38%), 38 are a BUY (35.51%).

Emmanuel Papadakis

Work Performance Price Targets & Ratings Chart

Analyst Emmanuel Papadakis works at DEUTSCHE BANK with a stock forecast success ratio of 51.47% fulfilled within 111.92 days on average.

Emmanuel Papadakis’s has documented 205 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AZN, AstraZeneca PLC ADR at 08-Feb-2024.

Wall Street Analyst Emmanuel Papadakis

Analyst best performing recommendations are on ALVO (ALVOTECH).
The best stock recommendation documented was for MRNA (MODERNA) at 3/7/2022. The price target of $155 was fulfilled within 9 days with a profit of $28.54 (22.57%) receiving and performance score of 25.08.

Average potential price target upside

AZN AstraZeneca PLC ADR GLPG Galapagos NV ADR GRFS Grifols SA ADR GSK GlaxoSmithKline PLC ADR MRNA Moderna NVO Novo Nordisk A/S NVS Novartis AG ADR SNY Sanofi ADR ARGX argenx NV ADR GMAB Genmab AS MOR MorphoSys AG ADR ALVO Alvotech LBTSF Almirall RHHBY Roche Holding Ltd ADR BNTX BioNTech SE

Analyst name


Current price target

Potential distance

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$12.3 (18.17%)


2 months 1 days ago

0/3 (0%)

$19.52 (32.28%)



$17.3 (25.55%)

2 months 21 days ago

0/11 (0%)

$19.26 (29.30%)



$2.3 (3.40%)

3 months 10 days ago

4/5 (80%)

$2.71 (4.03%)




9 months 1 days ago

0/6 (0%)

$75.62 (112.66%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Emmanuel Papadakis is most bullish on?

Potential upside of $19.91 has been obtained for MRNA (MODERNA)

Which stock is Emmanuel Papadakis is most reserved on?

Potential downside of -$0 has been obtained for AZN (ASTRAZENECA PLC ADR)

What Year was the first public recommendation made by Emmanuel Papadakis?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?